The MD Anderson Cancer Center, one of the largest and most prominent cancer research centers in the world, has released a clinical research study showing significant improvement of pain, anxiety, depression and sleep in advanced cancer patients who were treated with cranial electrotherapy stimulation (CES) via a handheld, non-invasive medical device called Alpha-Stim.
While Alpha-Stim is FDA cleared as a fast, safe and proven effective treatment for pain, anxiety, insomnia, and depression, and has more clinical research than any other device in its class, there are no published studies in patients with advanced cancer. The study examined the safety and efficacy of this non-drug treatment option, affirming years of research that Alpha-Stim is extremely effective, with no serious adverse effects and no risk of addiction, unlike opioids.
Daniel L. Kirsch, PhD, inventor of the Alpha-Stim and Chairman of Electromedical Products International, Inc., said that while the general belief has been that drugs are the most effective treatment, this study serves as a reminder that—even for advanced cancer patients who are routinely given prescription medications—the regular drugs that are being prescribed do not provide adequate treatment.
“The data gleaned from 36 years of use, over 15 million people treated, and from over 100 research studies tells a different truth,” said Kirsch, a board certified pain specialist. “In fact, we live in a drug culture. Nearly everyone who uses Alpha-Stim was already on drugs, but they either did not get an adequate effect from drugs or couldn’t tolerate their side effects. If drugs were safe and effective, there would be no Alpha-Stim. As clearly stated in this study, the effect was over and above that of the drugs they were on.”
Jeffrey Marksberry, MD, Vice President of Science and Education at EPI, noted that this study is especially important as Americans struggle with an on-going opioid epidemic that is fueled by current prescription medications.
“There is a current paradigm shift in medicine, moving away from medications riddled with side effects and addictive properties as is evident by the daily mention of the opioid epidemic on the nightly news,” said Marksberry. “In order to reduce our national dependence on prescription medication there has to be viable options available for practitioners and their suffering patients. The MD Anderson study proves that Alpha-Stim is a viable treatment option for pain, anxiety, insomnia and depression in one of the most difficult to treat patient populations.”
The results of this study come as the Trump Administration declares the opioid epidemic a national public health emergency. In a speech from the White House, President Trump called it the “worst drug crisis in American history,” as statistics show that the epidemic is killing more than 100 Americans each day.
Read the pre-released version of the study from MD Anderson Cancer Center on “Cranial Electrotherapy Stimulation for the Management of Depression, Anxiety, Sleep Disturbance, and Pain in Patients with Advanced Cancer: A preliminary study,” published by the Journal of Pain and Symptom Management, and see additional clinical research at www.alpha-stim.com.
Alpha-Stim® is a non-invasive prescription medical device (prescription not required outside the U.S.) that is FDA cleared to provide fast, safe and effective treatment of anxiety, insomnia, depression, and pain. The brain functions electrochemically and can be readily modified by electrical intervention. The Alpha-Stim utilizes cranial electrotherapy stimulation (CES) and microcurrent electrical therapy (MET) to deliver the only patented waveform which is clinically proven. Alpha-Stim can be used alone, along with other therapies, or as an adjunct to medication (without the risk of drug interactions). There are no serious adverse effects, no risk of addiction, and more than 100 research studies over 35 years that prove the effectiveness of this low level electrical prescription brain therapy. To learn more, call 1-800-FOR-PAIN or visit www.alpha-stim.com.
Full disclosure of the minor and self-limiting risks at www.alpha-stim.com/risk.
SOURCE Electromedical Products International, Inc.